Commenting on the Group’s performance in 2011, Sanofi Chief Executive Officer, Christopher A. Viehbacher said, “2011 was a key year in transforming Sanofi. We successfully acquired and integrated Genzyme, our growth platforms3 recorded double-digit growth, we delivered cost savings as planned and submitted filings to regulatory authorities for five new products. Several product exclusivity losses were absorbed and we successfully limited the impact on business EPS. Beyond the remaining patent cliff in 2012, the robust performance of our diversified growth platforms, the reduced exposure to future patent expiries and progress on R&D, position Sanofi for a period of sustainable growth”.
February 08, 2012